Venous thromboembolism prevention in patients with heart failure: An often neglected issue

Pathophysiology of Haemostasis and Thrombosis

Volumn 36, Issue 2, 2008, Pages 69-74

  Imberti, Davide ^a   Giorgi Pierfranceschi, Matteo ^a   Falciani, Michela ^b   Prisco, Domenico ^b  

^a GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Heart failure; Prophylaxis; Venous thromboembolism

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; NADROPARIN; PLACEBO;

BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEMATOMA; HUMAN; INFLAMMATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

DRUG TOXICITY; FIBRINOLYTIC AGENTS; HEART FAILURE; HUMANS; PREMEDICATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 58549120784     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173724     Document Type: Review

References (37)

1. Lindblad B, Sternby NH, Bergqvist D: Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991;302:709-711.
2. Goldhaber SZ, Savage DD, Garrison RJ, et al: Risk factors for pulmonary embolism: the Framingham study. Am J Med 1983;74:1023-1028.
3. Heit JA, Silverstein MD, Mohr DN, et al: Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.
4. Monreal M: Pulmonary embolism in patients with chronic obstructive pulmonary disease or congestive heart failure. Am J Med 2006;19:851-858.
5. Imberti D, Prisco D: Venous thromboembolism prophylaxis in medical patients: future perspectives. Thromb Res 2005;116:365-375.
6. Ageno W, Squizzato A, Garcia D, Imberti D: Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006;32:651-658.
7. Gruppo di lavoro per le linee guida sul tromboembolismo venoso della Società Italiana per lo Studio del'Emostasi e della Trombosi: Profilassi del tromboembolismo venoso in medicina. Haematologica 2003;88(suppl 18):50-53.
8. Seta Y, Shan K, Bozkurt B, et al: Basic mechanisms in heart failure: the cytokines hypotesis. J Card Fail 1996;2:243-249.
9. Cesari M, Penninx BW, Newman AB, et al: Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108:2317-2322.
10. Mann DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002;91:988-998.
11. Levi M, van der Poll T, Buller HR: Bidirectional relation between inflammation and coagulation. Circulation 2004;22:2698-2704.
12. Chin BS, Blann AD, Gibbs CR, et al: Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 2003;33:941-948.
13. Alehagen U, Dahlstrom U, Lindahl TL: Elevated D-dimer levels is an independent risk factor of cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost 2004;92:1250-1258.
14. Marcucci R, Gori AM, Giannotti F, et al: Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006;4:1017-1022.
15. Samama MM: An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-3420.
16. Di Minno G, Mannucci PM, Tufano A, et al: The first ambulatory screening on thromboembolism: a multicenter, cross-sectional, observational study on risk factors of venous thromboembolism. J Thromb Haemost 2005;3:1459-1466.
17. Howell MD, Geraci JM, Knowlton AA: Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol 2001;54:810-816.
18. Samama M, Cohen A, Darmon M, et al: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
19. Alikhan R, Cohen AT, Combe S, et al: Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003;14:341-346.
20. Leizorovich A, Cohen AT, Turpie G, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group: Randomized, placebo controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-879.
21. Cohen AT, Davidson BL, Gallus AS, et al: Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. Br Med J 2006;332:325-329.
22. Darze ES, Latado AL, Guimaraes AG, et al: Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 2005;128:2576-2580.
23. Cohen AT, Turpie AG, Leizorovicz A, et al: Thromboprophylaxis with dalteparin in medical patients: which patients benefit? Vasc Med 2007;12:123-128.
24. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, THE-PRINCE Study Group: Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614-621.
25. Geerts WH, Pineo GP, Heit JA, et al: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):338S-400S.
26. Hull R, Schellong S, Tapson V, et al: Extended thromboprophylaxis with enoxaparin in acutely ill patients with prolonged periods of immobilisation: the EXCLAIM Study. J Thromb Thrombolysis 2006;22:31-38.
27. Hull R, Schellong S, Tapson V, et al: Extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: the EXCLAIM study. J Thromb Haemost 2007;5(suppl 2):OS001.
28. Koch A, Bouges S, Ziegler S, et al: Low molecular weight heparin and unfractioned heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg 1997;84:750-759.
29. Fraisse F, Holzapfel L, Couland JM, et al: Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000;161:1109-1114.
30. Falciani M, Imberti D, Prisco D: Prophylaxis and treatment of venous thrombolembolism: the role of new antithrombotic drugs. Rec Prog Med 2005;96:196-204.
31. Cardiovascular Disease Educational and Research Trust, Cyprus Cardiovascular Disease Educational and Research Trust, European Venous Forum, International Surgical Thrombosis Forum; International Union of Angiology, Union Internationale de Phlébologie: Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006;25:101-161.
32. Hunt SA: ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Cardiol 2001;38:2101-2113.
33. Nieminem MS, Bohm M, Cowie MR, et al: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 2005;26:384-416.
34. Goldhaber SZ, Dunn K, MacDougall RC: New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by witholding treatment. Chest 2000;118:1680-1684.
35. Ageno W, Squizzato A, Ambrosini F, et al: Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 2002;87:746-750.
36. Goldhaber SZ, Tapson VF, DVT FREE Steering Committee: A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004;93:259-262.
37. Tapson VF, Decousus H, Pini M, et al, IMPROVE Investigators: Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry of Venous Thromboembolism. Chest 2007;132:936-945.